[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 747,927
  • Shares Outstanding, K 66,013
  • Annual Sales, $ 170,440 K
  • Annual Income, $ -193,880 K
  • EBIT $ -164 M
  • EBITDA $ -149 M
  • 60-Month Beta 0.94
  • Price/Sales 4.17
  • Price/Cash Flow N/A
  • Price/Book 8.12

Options Overview Details

View History
  • Implied Volatility 102.63% (-60.00%)
  • Historical Volatility 76.15%
  • IV Percentile 12%
  • IV Rank 9.28%
  • IV High 483.38% on 09/23/25
  • IV Low 63.68% on 09/05/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 110
  • Volume Avg (30-Day) 330
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 9,616
  • Open Int (30-Day) 8,012
  • Expected Range 11.07 to 11.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.36
  • Number of Estimates 5
  • High Estimate $-1.20
  • Low Estimate $-1.63
  • Prior Year $-1.20
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.18 +20.65%
on 07/28/26
11.50 -3.74%
on 08/06/26
+1.18 (+11.93%)
since 07/17/26
3-Month
5.50 +101.27%
on 05/19/26
15.88 -30.29%
on 07/08/26
+5.42 (+95.93%)
since 05/18/26
52-Week
5.45 +102.93%
on 05/18/26
16.19 -31.62%
on 01/22/26
+2.36 (+27.10%)
since 08/18/25

Most Recent Stories

More News
Regenxbio: Q2 Earnings Snapshot

Regenxbio: Q2 Earnings Snapshot

RGNX : 11.07 (-2.29%)
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md. , Aug. 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.

RGNX : 11.07 (-2.29%)
REGENXBIO's Pivotal Duchenne Data Casts a Shadow Over Tomorrow's Cash Runway Disclosure

Barchart Research What to Expect from RGNX Earnings RGNX Generated August 5, 2026 Current Price $10.50 EPS Estimate $$0.12 Consensus Rating Moderate Buy Average Move 8.79% REGENXBIO's Pivotal Duchenne...

RGNX : 11.07 (-2.29%)
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md. , Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results...

RGNX : 11.07 (-2.29%)
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) ...

RGNX : 11.07 (-2.29%)
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

ROCKVILLE, Md., , July 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314)...

RGNX : 11.07 (-2.29%)
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

ROCKVILLE, Md. , July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per...

RGNX : 11.07 (-2.29%)
REGENXBIO Announces Proposed Public Offering of Common Stock

ROCKVILLE, Md. , July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an...

RGNX : 11.07 (-2.29%)
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

ROCKVILLE, Md. , June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene...

RGNX : 11.07 (-2.29%)
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

ROCKVILLE, Md. , June 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene...

RGNX : 11.07 (-2.29%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 11.74
2nd Resistance Point 11.47
1st Resistance Point 11.27
Last Price 11.07
1st Support Level 10.80
2nd Support Level 10.53
3rd Support Level 10.33

See More

52-Week High 16.19
Fibonacci 61.8% 12.09
Last Price 11.07
Fibonacci 50% 10.82
Fibonacci 38.2% 9.56
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.